Related Experiment Video
Updated: Oct 16, 2025
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
Published on: January 20, 2023
Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data
Poul F Høilund-Carlsen1,2, Abass Alavi3
1Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
Abstract:
According to the FDA, aducanumab (Aduhelm), the recently approved anti-Alzheimer drug, reduces the level of cerebral amyloid plaques-a hallmark finding in patients with Alzheimer's disease-and this will result in a reduction in clinical decline. The authors of this article are not convinced that amyloid deposits are a hallmark of Alzheimer's disease and are of the opinion that the apparent reduction in amyloid accumulation following aducanumab treatment is likely instead a result of continued and advanced cerebral cell death and, thus, not a sign of improvement but of an even more advanced disease.
Insights
Aducanumab (Aduhelm) may not improve Alzheimer's disease. Researchers question if reduced amyloid plaques signify healing or advanced brain cell death, suggesting it could indicate a worsening condition.
Area of Science:
- Neurology
- Neurodegenerative Diseases
- Alzheimer's Disease Research
Background:
- The U.S. Food and Drug Administration (FDA) approved aducanumab (Aduhelm) as an anti-Alzheimer's drug.
- Aducanumab is believed to reduce cerebral amyloid plaques, a key indicator in Alzheimer's disease patients.
- This reduction is proposed to correlate with a decrease in clinical decline.
Purpose of the Study:
- To critically evaluate the interpretation of aducanumab's effect on cerebral amyloid plaques.
- To investigate whether reduced amyloid accumulation represents disease improvement or signifies advanced cerebral cell death.
Main Methods:
- Review and critical analysis of existing data on aducanumab's mechanism of action.
- Interpretation of amyloid plaque reduction in the context of Alzheimer's disease pathology.
Main Results:
- The authors contest the notion that amyloid deposits are a definitive hallmark of Alzheimer's disease.
- They propose that aducanumab-induced reduction in amyloid plaques may stem from increased cerebral cell death.
- This suggests that plaque reduction might not indicate therapeutic benefit but rather disease progression.
Conclusions:
- The efficacy of aducanumab in treating Alzheimer's disease is questioned.
- The observed reduction in amyloid plaques should not be automatically interpreted as a positive clinical outcome.
- Further research is needed to understand the true impact of aducanumab on Alzheimer's disease progression and pathology.
